Clinical trial Recruiting at 1 site Observational Ages 18 and up

Pre-hospital ARNI use and short-term outcomes in HFrEF

Official title: Evaluating the Impact of Pre-Hospital Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy on Short-Term Clinical Outcomes in Heart Failure Patients With Reduced Ejection Fraction: A Comparative Study

Run by Future University in Egypt · NCT07347925 · Data updated 2026-11-12

This project will see if people with heart failure and low ejection fraction who were taking an ARNI before coming to the hospital have better short-term outcomes than those who weren't.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment140 (estimated)
SponsorFuture University in Egypt
Academic / other
Locations1 site (Al Mansurah)
StatusRecruiting
StartedJanuary 10, 2026
Main results expectedApril 15, 2026
Study endsMay 1, 2026
Registry record updatedJanuary 16, 2026
Trial IDNCT07347925 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older hospitalized with heart failure and an ejection fraction below 40% with verifiable pre-admission medication history are the ideal candidates.

Probably not a fit

Patients with preserved ejection fraction (>40%), pregnant or breastfeeding individuals, or those without reliable medication records are unlikely to be included or to directly benefit from the study findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares adults admitted with heart failure and left ventricular ejection fraction under 40% who were taking an angiotensin receptor–neprilysin inhibitor (sacubitril/valsartan) before hospital arrival to those who were not. Investigators will extract data from hospital records to record cardiac events, kidney-related events, length of stay, and selected short-term outcomes, with some participants followed briefly after discharge. No treatments are assigned as part of the study; analyses will adjust for baseline clinical differences to explore associations between pre-hospital ARNI use and outcomes. The work is conducted at a single center (Mansoura University Hospital) and reflects routine clinical care in that setting.

Why it matters

Potential benefit: If positive, the results could clarify whether prior ARNI use is linked to fewer in-hospital cardiac or renal complications and shorter hospital stays, informing real-world management of HFrEF.

How similar studies have gone: Randomized trials have shown long-term mortality and morbidity benefits of sacubitril/valsartan in HFrEF, but evidence specifically about pre-hospital ARNI use and short-term in-hospital outcomes is limited and mainly observational.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* \>= 18 years, male or female EF \<40%

Exclusion Criteria:

* EF\>40% Pregnancy or breastfeeding

Where it's running

  • Mansoura university Hospital
    Al Mansurah, Egypt
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.